Decoding methods are provided for identifying populations in assays, particularly multiplexing assays and those associated with fluidic devices.

Described herein is a beads-free bioprocessor as an automated and cost-effective T cell processing and manufacturing platform. T cells are a core component in CAR T cell therapies for cancer treatment, but are difficult to manufacture to scale in clinically relevant quantities. The 3D bioprocessor provides an alternative device that is scalable, beads-free, easy-to-use, and cost-effective for using CAR T cell therapy in cancer immunotherapy. Besides CAR T cell application, this platform technology has potential for many other applications such as cancer cell isolation.

A method of assaying biological content of a sample, termed “microsphere-based binding assay”, using microspheres made of polystyrene or other materials to capture and detect in a sample one or more biomarkers that may be present in the biological sample. The method is able to measure various antibodies associated with infection or vaccine response. Microspheres can be coated with capture antigens and exposed to multiple sets of biomarkers. The biomarkers can be fluorescently active or fluorescently labeled. The method analyzes the fluorescent profile using scanning cytometry. Increased safety, reliability and efficiency is achieved over prior art methods.

The invention concerns a method for detecting indicators for determining diseases (disease indicators), in which aggregates of misfolded proteins play a role, and a method for selective quantitation and/or characterization of these disease indicators.

Provided is a membrane carrier for a test kit for detecting a substance to be detected in a liquid sample, the membrane carrier including: a flow channel having a detection zone, in which the flow channel has a rough structure A having protrusions, at least in the detection zone, a rough microstructure B is formed on a surface of the protrusion, a silane coupling agent is attached to a surface of the rough microstructure B, and a maximum peak height Rp of a roughness curve of a protrusion at which the rough microstructure B is formed, as measured according to JIS B0601: 2013 using a three-dimensional roughness analysis scanning electron microscope, is equal to or more than 0.005 μm and equal to or less than 10 μm, and an average length RSm of a roughness curve element is equal to or more than 0.01 μm and equal to or less than 15 μm.

The present technology generally relates to stopped-flow microfluidic devices. Select embodiments of the present technology include microfluidic devices having a first porous element configured to receive a first fluid and a second porous element configured to receive a second fluid. The second porous element can have one or more legs overlapping with the first porous element. The device can be configured such that (a) delivery of the first fluid to the first porous element causes the first fluid to flow along the length of the first porous element without substantially wetting the one or more legs, and (b) delivery of the second fluid to the second porous element causes the second fluid to flow into the overlapping regions of the first porous element, thereby substantially stopping flow of the first fluid along at least a portion of the first porous element.

Among other things, the present disclosure is related to devices and methods of performing biological and chemical assays, such as but not limited to immunoassays and nucleic assay acid, particularly a homogeneous assay that does not use a wash step and that is fast (e.g., 60 seconds from dropping a sample to displaying results). The present disclosure is related to both competitive and non-competitive homogeneous assays.

The methods, compositions and systems provided herein use functionalized beads to detect a target microparticle in a test sample, the method comprising (a) contacting the test sample containing the target microparticle with a plurality of functionalized beads. The size of the target microparticle is less than 1 μm. The functionalized beads comprise beads coated with molecules of a capture agent, and at least some molecules of the capture agent bind to the target microparticle, thereby forming target microparticle-loaded beads comprising the functionalized beads and the target microparticle. The method further comprises (b) detecting the target microparticle-loaded beads using a flow cytometer, thereby detecting the presence of the target microparticle in the test sample, and the target microparticle-loaded the beads are detected with the detection limit that ranges from 10 microparticles per ml to 10e4 microparticles per ml.

Described is a method and device for detecting an analyte in a sample, comprising bringing a sample comprising a target analyte into contact with magnetisable particles, the particles being coated with binding molecules complementary to the target analyte, resulting in bound and unbound binder complexes, positioning the magnetisable particles, comprising both bound and unbound binder complexes, in proximity to a magnetic field sensor, changing the magnetic field sufficient to release at least a portion of the magnetisable particles, comprising both bound and unbound binder complexes, from their proximity to the magnetic field sensor, and measuring changes in a magnetic signal detected from the net movement, being either translational or rotational movement, of the magnetisable particles relative to the magnetic sensor.

Provided is a method for detecting a test substance, the method including the steps of: forming an immune complex on a first solid phase by bringing a test substance, a labeled antibody, a capture antibody and the first solid phase into contact with one another; transferring the immune complex onto a second solid phase by breaking the binding between the capture antibody and the first solid phase to liberate the immune complex, and bringing the second solid phase and the immune complex into contact with each other, where the second solid phase is bound to the capture antibody; and detecting the test substance by measuring a label contained in the complex on the second solid phase. The test substance detected by the method is a multimeric antigen, particularly amyloid β or tau protein.